Brief: Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia
24/04/2025 13:17
April 24 (Reuters) - Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS OF AN INVESTIGATOR-INITIATED OPEN LABEL STUDY WITH LOW-DOSE IL-2 AND CTLA4-IG COMBINATION TREATMENT IN FIVE PATIENTS WITH MILD TO MODERATE FRONTOTEMPORAL DEMENTIA COYA THERAPEUTICS INC - STUDY SHOWS SIGNIFICANT INCREASE IN TREG NUMBERS AND FUNCTION COYA THERAPEUTICS INC - FTD PATIENTS SHOW MINIMAL TO NO COGNITIVE DECLINE IN STUDY Source text: ID:nBw9kFZSFa Further company coverage: COYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)